---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-403429"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2026-09-28T12:10:41+00:00"
generated_at: "2026-10-12T13:31:08.885791+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics receives $15.0M CIRM CLIN2 grant for Phase 2 RECLAIM-LN trial of FT819

## Summary
- CIRM awarded Fate a $15.0 million CLIN2 grant on Sept 25, 2026 to support RECLAIM-LN, the Phase 2 potentially registrational trial of FT819.
- RECLAIM-LN (FT819-201; NCT07570862) plans to enroll approximately 53 refractory SLE patients with lupus nephritis; primary endpoint is complete renal response at Week 26.
- FT819 is an off-the-shelf iPSC-derived CAR T-cell therapy; Phase 1 data showed favorable safety and clinically meaningful SLEDAI-2K and UPCr improvements.
- FT819 holds FDA RMAT designation and was selected for the FDA's CMC Development and Readiness Pilot (CDRP) program.

## SEC filing metadata
- accession: 0001193125-26-403429
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2026-09-28T12:10:41+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/0001193125-26-403429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312526403429/fate-20260925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-403429
- JSON: https://secwatch.observer/filing/0001193125-26-403429.json
- Plain text: https://secwatch.observer/filing/0001193125-26-403429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.